Oculis is a clinical-stage biopharmaceutical company, founded in 2017, dedicated to developing innovative topical treatments in the form of eye drops for ophthalmic diseases affecting both the back and front of the eye. The company’s mission is to improve the lives of patients worldwide by advancing non-invasive, effective therapies that address unmet medical needs in eye care. Through a strong focus on research and clinical development, Oculis aims to deliver novel solutions that enhance treatment outcomes and patient quality of life across a wide range of ophthalmic conditions.